Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on March 5, 2014. The filing discloses the entry into a definitive material loan agreement and a pharmaceutical supply agreement, alongside the termination of a prior loan agreement.
Key Financial Metrics and Agreements
Loan Agreement
- Principal Amount: $32.0 million borrowed from Oxford Finance LLC and MidCap Financial SBIC, LP.
- Use of Proceeds: Approximately $19.1 million used to repay the prior loan agreement; remaining proceeds designated for general corporate purposes and working capital.
- Interest Rate: Fixed annual rate of 9.25%.
- Repayment Terms: Interest-only payments monthly through March 1, 2015. Principal and interest payments commence April 1, 2015, with a maturity date of March 1, 2018.
- Fees: $160,000 upfront facility fee; 7.00% final payment fee ($2.2 million) payable at maturity or upon prepayment; 1.00% prepayment fee on prepaid principal.
- Collateral: Security interest in substantially all assets, excluding intellectual property.
- Covenants: No cash covenants; includes customary restrictions on indebtedness, liens, mergers, asset dispositions, and dividends.
DSM Supply Agreement
- Counterparty: DSM Pharmaceuticals, Inc.
- Product: Omidria (ophthalmologic product candidate).
- Term: Through December 31, 2015.
- Commitments: Omeros must purchase a minimum percentage of commercial requirements based on rolling forecasts after FDA approval. No minimum purchase commitments exist prior to approval.
Material Changes Versus Prior Period
The company terminated its prior Loan and Security Agreement dated October 21, 2010, and all associated security interests were released. This was replaced by the new $32.0 million facility, which extends the maturity date to 2018 and alters the fee structure and repayment schedule.
Guidance, Outlook, Risks, and Contingencies
The filing does not provide specific financial guidance or revenue outlook. Key risks and contingencies include:
- Default Risks: Events of default include non-payment, covenant breaches, material adverse changes, and bankruptcy. Default triggers a 5.00% penalty interest rate and potential acceleration of obligations.
- Supply Chain Risk: The DSM Supply Agreement may be terminated if a regulatory authority prohibits manufacture at DSM's facility, though Omeros retains the right to request assistance in transferring the process.
- Liquidity: Proceeds are intended to support working capital, indicating a focus on maintaining operational liquidity.
Important Facts for Investor Verification
- Verify the exact amount of the "Prior Agreement" repaid ($19.1 million) against previous filings to confirm the net new capital raised.
- Confirm the status of FDA approval for Omidria, as this triggers the minimum purchase commitments under the DSM Supply Agreement.
- Review the full text of the Loan Agreement (Exhibit 10.1) for specific definitions of "Material Adverse Change" and other covenant exceptions.
- Monitor the company's cash burn rate to ensure it can meet the interest-only payments through March 2015 and the subsequent principal amortization.